Ma ka OASIS Phase IIIa study, oral semaglutide 50 mg i kēlā me kēia lā i kōkua i ke kaumaha nui a i ʻole nā mea nui e lilo i 15.1% o ko lākou kaumaha kino, a i ʻole 17.4% inā pili lākou i ka mālama ʻana, hōʻike ʻo Novo Nordisk.ʻO ka 7 mg a me 14 mg oral semaglutide variants i kēia manawa i ʻae ʻia no ka type 2 diabetes ma lalo o ka inoa Rybelsus.
I ka laina me nā haʻawina mua, ua ʻike ʻia ka haʻawina Bavarian e pili ana kahi maʻi COVID-19 me ka piʻi ʻana o ka maʻi diabetes type 1 i nā keiki.(ʻAhahui Lapaʻau ʻAmelika)
Ke ʻimi nei ka United States Preventive Services Task Force (USPSTF) i ka manaʻo o ka lehulehu e pili ana i kāna palapala hoʻolālā no ka noiʻi ʻana i nā hana hoʻemi kaumaha e pale ai i ka morbidity pili i ka momona a me ka make i nā pākeke.
Hoʻohālikelike ʻia me nā wahine me ka maʻi maʻi ʻole, ʻo nā wahine waena me ka prediabetes (ke koko koko hoʻokēʻai ma waena o 100 a me 125 mg/dL) he 120% ʻoi aʻe ka loaʻa ʻana o nā haʻi i ka wā a ma hope o ka hoʻololi menopausal.(Wehe ʻia ka pūnaewele JAMA)
Ua hoʻolaha ʻo Valbiotis ʻo Totum 63, kahi hui noiʻi o ʻelima mau mea kanu mea kanu, ua hoʻemi nui ʻia ka pae glucose koko hoʻokēʻai i nā mea maʻi me ka pre-diabetes a me ka maʻi diabetes type 2 mua ʻole i ka Phase II/III REVERSE-IT study.
ʻO ka semaglutide lāʻau paona kaumaha (Wegovy) hiki ke hōʻemi i ka hopena o ka maʻi puʻuwai, e like me nā hopena hoʻokolokolo mua.(Reuters)
He mea kākau limahana ʻo Kristen Monaco i loea i ka endocrinology, psychiatry a me nephrology news.Ua hoʻokumu ʻia ʻo ia ma ke keʻena ʻo New York mai 2015.
ʻO nā mea ma kēia pūnaewele no nā kumu ʻike wale nō a ʻaʻole ia he pani no ka ʻōlelo aʻoaʻo lapaʻau, ʻike ʻike, a i ʻole ka mālama ʻana mai kahi mea mālama olakino kūpono.© 2005–2022 MedPage Today, LLC, he hui ʻo Ziff Davis.Ua mālama ʻia nā kuleana āpau.ʻO Medpage Today kekahi o nā hōʻailona kālepa federally o MedPage Today, LLC a ʻaʻole hiki ke hoʻohana ʻia e nā ʻaoʻao ʻekolu me ka ʻole o ka ʻae ʻia.
Ka manawa hoʻouna: Iune-15-2023